Amarin Corporation highlighted new clinical data at the 2026 American Heart Association Scientific Sessions showing that VASCEPA (icosapent ethyl) reduces major cardiovascular events associated with elevated Lipoprotein(a) [Lp(a)] levels, even when LDL cholesterol is controlled by statins. The data also reveal that Lp(a) oxidation promotes inflammation and oxidative stress, which VASCEPA helps mitigate. This is significant following a recent trial failure of another Lp(a)-lowering drug, emphasizing VASCEPA's unique benefit in reducing residual cardiovascular risk. The findings support VASCEPA's role as an available therapy that lowers cardiovascular events across different Lp(a) levels.
Amarin Corporation's new data on Lipoprotein(a) offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced US health stocks, 121 rose and 18 fell. Notable movers include ABEO at USD 3.65 with a -12.47% change, IMVT at USD 33.50 up 9.73%, and INO at USD 1.32 up 8.64%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
